Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million ...

When I co-invented the first PET (positron emission tomography) scan to visualize brain amyloid and tau—the physical evidence of Alzheimer’s disease—I did not foresee the distressing mental ...

Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

In the US, patients can be approved for the new medications if a radioactive PET scan shows beta-amyloid buildup in the brain, a typical symptom of Alzheimer’s. But because people with vascular ...

A new study finds that brain shrinkage in Alzheimer’s disease varies greatly among individuals, with distinct patterns rather than a uniform progression. These findings may pave the way for ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

In the rapidly evolving field of neuroimaging, the convergence of engineering advancements and medical expertise is reshaping our approach to understanding and treating neurological disorders. This ...

Voyager Therapeutics Inc (VYGR) reports a robust financial runway and advances in Alzheimer's research, despite challenges in ...